Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Remix Therapeutics
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Both Atlas and Foresite Capital announced new funds focused on start-ups. Also, Flagship launched Vesalius with $75m in initial funding, Innoviva sold $225m in notes, Hookipa priced a $75m follow-on offering and job cuts were revealed by Epizyme, Flexion, Deciphera and Gemini.
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Gene Therapy, Cell Therapy